Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303206 | 0.96 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15100 | 0.96 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL11812350 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL232280 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL18952368 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| Water SCHEMBL14775667 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10454769 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5407634 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL986707 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14912272 | 0.93 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736201-B | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-114736201-A | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-07-12 | — | — | CN | claimed |
| US-20250214918-A1 | FUNCTIONALIZATION OF TERPENES BY SELECTIVE DEPROTONATION FOR THE SYNTHESIS OF (+)-ARTEMISININ AND RELATED COMPOUNDS | UNIV TEXAS (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2025122555-A1 | S1P 1 RECEPTOR AGONISTS AND USES THEREOF | VALO HEALTH, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2023225681-A9 | S HOPINGFUNCTIONALIZATION OF TERPENES BY SELECTIVE DEPROTONATION FOR THE SYNTHESIS OF (+)-ARTEMISININ AND RELATED COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYTEM (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225681-A2 | S HOPINGFUNCTIONALIZATION OF TERPENES BY SELECTIVE DEPROTONATION FOR THE SYNTHESIS OF (+)-ARTEMISININ AND RELATED COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-114736201-B | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114736201-A | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-1010703-B1 | Process for preparing aryl metal compounds and their conversion with electrophiles | MERCK PATENT GMBH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6207835-B1 | DEPROTONATION IN CONTINUOUS FLOW REACTOR | MERCK KGAA (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-1010703-A2 | Process for preparing aryl metal compounds and their conversion with electrophiles | MERCK PATENT GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214918-A1 | FUNCTIONALIZATION OF TERPENES BY SELECTIVE DEPROTONATION FOR THE SYNTHESIS OF (+)-ARTEMISININ AND RELATED COMPOUNDS | DHPS, SQLE, CYP11B2 | ALDH1A1 157/4885SMN1; SMN2 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.